8月25日，洁雅股份跌0.83%，成交额1.43亿元。两融数据显示，当日洁雅股份获融资买入额1215.99万 元，融资偿还1541.10万元，融资净买入-325.11万元。截至8月25日，洁雅股份融资融券余额合计 5208.69万元。 截至8月20日，洁雅股份股东户数8193.00，较上期减少5.27%；人均流通股7891股，较上期增加5.57%。 2025年1月-3月，洁雅股份实现营业收入1.24亿元，同比减少4.62%；归母净利润1006.27万元，同比减少 27.61%。 分红方面，洁雅股份A股上市后累计派现1.39亿元。近三年，累计派现7780.82万元。 责任编辑：小浪快报 融券方面，洁雅股份8月25日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，铜陵洁雅生物科技股份有限公司位于安徽省铜陵市狮子山经济开发区铜井东路1928号，成立 日期1999年8月31日，上市日期2021年12月3日，公司主营业务涉及湿巾类产品研发、生产与销售。主营 业务收入构成为：湿巾类产品90.50%，面膜 ...

Company Overview - Tongling Jieya Biotechnology Co., Ltd. was established in 1999, specializing in the research, production, and sales of wet wipes, with over 20 years of industry experience [1] - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on December 3, 2021, and is steadily advancing its fundraising projects [1] - In Q1 2025, the company reported a revenue of 124 million yuan and a net profit of 1,006.27 thousand yuan [1] U.S. Factory Development - The U.S. wet wipes factory is currently under construction and is expected to commence production next year [2] - To manage higher labor costs in the U.S., the factory will implement automated production lines and optimize management processes to enhance operational efficiency and cost structure [2] - Key investment risks for the U.S. factory include uncertainties in facility renovation and approval processes, customer audit outcomes, potential delays in production start, and cultural differences affecting production efficiency [2] Customer Relations and Market Strategy - The company primarily relies on forecast orders from clients, which are mostly well-known global enterprises, ensuring stable cooperation [3] - The company is focused on optimizing its business structure and enhancing core competitiveness through technological innovation [3] - The Shanghai R&D center is dedicated to independent research and development of cosmetic formulations and collaboration with domestic and international clients [3] Business Performance and Future Outlook - Since Q2 2025, the wet wipes business has seen a stable order flow, with existing clients maintaining orders and new business opportunities in Europe and Canada [4] - The company is actively expanding its market presence with international brand clients [4] - Future business drivers include expanding product categories and sales regions based on existing brand clients and leveraging the U.S. factory [4] Financial Management - The company has approximately 600 million yuan of idle fundraising capital allocated for principal-protected financial products, ensuring the safety of investments while supporting ongoing projects [4] - The company adheres to regulatory guidelines to prevent the disclosure of undisclosed significant information during investor communications [4]

Company Overview - Tongling Jeya Biotechnology Co., Ltd. was established in 1999 and specializes in the research, production, and sales of wet wipes, accumulating over 20 years of industry experience [2]. - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on December 3, 2021, and is steadily advancing its fundraising projects [2]. Financial Performance - In Q1 2025, the company reported a revenue of 124 million yuan and a net profit of 10.06 million yuan [2]. Q&A Highlights - **Impact of Tariff Policies**: Current tariff adjustments have not significantly affected the company's operations, and the overall impact is manageable [3]. - **U.S. Production Base**: The construction of the U.S. production base is progressing as planned, currently in the foundational construction phase, with production expected to commence in 2025 [3]. - **Performance Trends**: The company has stabilized its performance through business restructuring and successfully acquired Kimberly-Clark's European business [3]. - **Personal Care Business Development**: The personal care segment primarily focuses on OEM for L'Oréal, with plans to expand domestic clientele, although current order volumes are small. Future growth may involve industry acquisitions [3]. - **Strategic Development Direction**: The company aims to deepen existing business operations while exploring innovative fields such as biosynthesis technology and core materials for the health industry [3]. - **Own Brand Consideration**: The company has initiated incubation trials through an industrial fund, focusing on online marketing, though market conversion rates have not met expectations [3]. - **Customer Dependency Risks**: The company collaborates with well-known global enterprises, ensuring stable partnerships. Major clients have stringent quality requirements and established supplier certification systems, making supplier changes infrequent. The company plans to optimize its business structure and enhance core competitiveness through technological innovation [3]. Compliance and Regulations - The investor communication event adhered strictly to the Shenzhen Stock Exchange's self-regulatory guidelines, ensuring no significant undisclosed information was leaked [3].